Search results for "Randomized controlled trial."

showing 10 items of 2199 documents

Protective Effects of Statins Administration in European and North American Patients Infected with COVID-19: A Meta-Analysis

2021

AbstractSevere acute respiratory syndrome coronavirus 2 has spread rapidly throughout the world, becoming an overwhelming global health emergency. The array of injuries caused by this virus is broad and not limited to the respiratory system, but encompassing also extensive endothelial and systemic tissue damage. Since statins effectively improve endothelial function, these drugs may have beneficial effects in patients with coronavirus disease 2019 (COVID-19). Therefore, this investigation aimed to provide an updated overview on the interplay between statins and COVID-19, with particular focus on their potentially protective role against progression toward severe or critical illness and deat…

0301 basic medicinemedicine.medical_specialtyStatinmedicine.drug_class030204 cardiovascular system & hematologyStatins COVID-19 Meta-analysislaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineAdjuvant therapyGlobal healthHumansSARS-CoV-2business.industryStatinsCOVID-19HematologyOdds ratioUnited StatesConfidence intervalCOVID-19 Drug TreatmentReview articleEuropeHospitalizationMeta-analysis030104 developmental biologyMeta-analysisHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessSeminars in Thrombosis and Hemostasis
researchProduct

Association of statin use and clinical outcomes in heart failure patients : a systematic review and meta-analysis

2019

Abstract Background The role of statins in patients with heart failure (HF) of different levels of left ventricular ejection fraction (LVEF) remains unclear especially in the light of the absence of prospective data from randomized controlled trials (RCTs) in non-ischemic HF, and taking into account potential statins’ prosarcopenic effects. We assessed the association of statin use with clinical outcomes in patients with HF. Methods We searched PubMed, EMBASE, Scopus, Google Scholar and Cochrane Central until August 2018 for RCTs and prospective cohorts comparing clinical outcomes with statin vs non-statin use in patients with HF at different LVEF levels. We followed the guidelines of the 2…

0301 basic medicinemedicine.medical_specialtyStatinmedicine.drug_classEndocrinology Diabetes and MetabolismClinical Biochemistry610Heart failure030204 cardiovascular system & hematologyLower risklaw.invention03 medical and health sciences0302 clinical medicineEndocrinologyRandomized controlled trialHeart failure; Hospitalization; Meta-analysis; Mortality; StatinslawInternal medicineHumansMedicineCardiac and Cardiovascular SystemsProspective StudiesMortalitylcsh:RC620-627Kardiologibusiness.industryResearchBiochemistry (medical)Hazard ratioStatinsmedicine.diseaseConfidence interval3. Good healthHospitalizationlcsh:Nutritional diseases. Deficiency diseasesMeta-analysisTreatment Outcome030104 developmental biologyMeta-analysisHeart failureHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCohort study
researchProduct

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

2019

Background Six months of adjuvant oxaliplatin-based chemotherapy is standard for patients with stage III colon cancer following surgery. However, oxaliplatin is associated with peripheral neurotoxicity which worsens over treatment duration. Consequently, a shorter treatment duration, if equally effective, would be extremely beneficial. A pooled analysis of data for 12 834 stage III colon cancer patients, from six randomised phase III trials of adjuvant therapy, the International Duration Evaluation of Adjuvant chemotherapy study, was carried out and the results presented at the ASCO Annual Meeting 2017. To clarify the potential impact of these results on clinical practice, ESMO decided to s…

0301 basic medicinemedicine.medical_specialtyTime FactorsColorectal cancerRisk AssessmentDisease-Free Survival03 medical and health sciences0302 clinical medicineFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAdjuvant therapyHumansMulticenter Studies as TopicColectomyNeoplasm StagingRandomized Controlled Trials as Topicbusiness.industryCAPOX RegimenHematologyCongresses as Topicmedicine.diseaseChemotherapy regimenOxaliplatinClinical trialOxaliplatinRegimen030104 developmental biologyOncologyClinical Trials Phase III as TopicChemotherapy Adjuvant030220 oncology & carcinogenesisData Interpretation StatisticalColonic NeoplasmsPractice Guidelines as TopicQuality of LifeNeurotoxicity Syndromesbusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Women in LOVe: Lacto-Ovo-Vegetarian Diet Rich in Omega-3 Improves Vasomotor Symptoms in Postmenopausal Women. An Exploratory Randomized Controlled Tr…

2019

Objective:In the postmenopausal period, most women suffer vasomotor symptoms (VMS). It is well-known that VMS can worsen the quality of life. Diet seems to play a relevant role in the development of VMS, but the effect of diet on VMS is mainly limited to observational studies, and analyses of nutritional supplements. The aim of this study was thus to determine the efficacy of a lactoovo- vegetarian (LOVe) diet rich in omega-3 fatty acids vs. a lacto-ovo-vegetarian diet rich in EVO (extra-virgin olive oil) in reducing VMS frequency in postmenopausal women.Methods:A two-arms (lacto-ovo-vegetarian diet with EVO vs. lacto-ovo-vegetarian diet rich in omega-3) randomized-controlled trial with a f…

0301 basic medicinemedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismSweatinglaw.invention03 medical and health sciences0302 clinical medicinePrimary outcomeRandomized controlled triallawInternal medicineFatty Acids Omega-6medicineImmunology and AllergyHumans030212 general & internal medicine030109 nutrition & dieteticsPostmenopausal womenVasomotorbusiness.industryDiet VegetarianAnthropometryMiddle Agedmedicine.diseaseMenopausePostmenopauseVasomotor SystemTreatment OutcomeItalyHot FlashesObservational studyFemaleDiet menopause omega 3 lacto-ovo-vegetarian RCT Kupperman indexbusinessNutritive ValueBiomarkersOlive oilVegetariansEndocrine, metabolicimmune disorders drug targets
researchProduct

Randomized controlled trial comparing embryo culture in two incubator systems: G185 K-System versus EmbryoScope

2017

Objective To study whether the closed culture system, as compared with a benchtop incubator with similar culture conditions, has a positive impact on intracytoplasmic sperm injection (ICSI) outcomes. Design Randomized controlled trial. Setting University hospital. Patient(s) A total of 386 patients undergoing ICSI cycles with at least six mature oocytes were randomized. Intervention(s) Of these patients, 195 were assigned to the group with culture in a time-lapse imaging (TLI) system (EmbryoScope) and 191 to the group with culture in the G185 K-System (G185). Main Outcome Measure(s) Rate of implantation (primary endpoint) and embryo morphology grade. Result(s) No significant differences wer…

0301 basic medicinemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentBiologyTime-Lapse ImagingIntracytoplasmic sperm injectionlaw.inventionEmbryo Culture TechniquesHospitals UniversityIncubators03 medical and health sciences0302 clinical medicineRandomized controlled trialEmbryo cryopreservationPregnancyRisk FactorslawOdds RatiomedicineClinical endpointHumansEmbryo ImplantationProspective StudiesSperm Injections IntracytoplasmicGynecologyMicroscopy Video030219 obstetrics & reproductive medicineObstetrics and GynecologyEmbryo cultureEmbryoEquipment DesignEmbryo TransferConfidence intervalEmbryo transferLogistic ModelsTreatment Outcome030104 developmental biologyReproductive MedicineInfertilityMultivariate AnalysisFemaleFranceMaternal AgeFertility and Sterility
researchProduct

Magnesium and health outcomes: An umbrella review of systematic reviews and meta-analyses of observational and intervention studies

2020

Purpose: To map and grade all health outcomes associated with magnesium (Mg) intake and supplementation using an umbrella review. Methods: Umbrella review of systematic reviews with meta-analyses of observational studies and randomized controlled trials (RCTs) using placebo/no intervention as control group. We assessed meta-analyses of observational studies based on random-effect summary effect sizes and their p values, 95% prediction intervals, heterogeneity, small-study effects and excess significance. For meta-analyses of RCTs, outcomes with a random-effect p value < 0.005 and a high-GRADE assessment were classified as strong evidence. Results: From 2048 abstracts, 16 meta-analyses an…

0301 basic medicinemedicine.medical_specialtyUmbrella review.Settore MED/09 - Medicina InternaHealth StatusMedicine (miscellaneous)030209 endocrinology & metabolismType 2 diabetesPlaceboDiabetelaw.inventionMagnesium Meta-analysis Pregnancy Diabetes Stroke Umbrella reviewUmbrella review03 medical and health sciences0302 clinical medicineRandomized controlled triallawPregnancyInternal medicinemedicineHumansMeta-analysiMagnesiumStroke030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryDiabetesmedicine.diseaseStrokeMeta-analysisObservational Studies as TopicSystematic reviewMigraineMeta-analysisDietary SupplementsObservational studybusiness
researchProduct

Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials.

2019

International audience; Recently, concerns regarding the safety of red yeast rice (RYR) have been raised after the publication of some case reports claiming toxicity. Since the previous meta-analyses on the effects of RYR were mainly focused on its efficacy to improve lipid profile and other cardiovascular parameters, we carried out a meta-analysis on safety data derived from the available randomized controlled clinical trials (RCTs). Primary outcomes were musculoskeletal disorders (MuD). Secondary outcomes were non-musculoskeletal adverse events (Non-MuD) and serious adverse events (SAE). Subgroups analyses were carried out considering the intervention (RYR alone or in association with oth…

0301 basic medicinemedicine.medical_specialty[SDV]Life Sciences [q-bio]PlaceboMusculoskeletal disorderslaw.invention03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRandomized controlled triallawInternal medicineNon-musculoskeletal adverse eventmedicineRed yeast riceHumansMusculoskeletal DiseasesAdverse effectRandomized Controlled Trials as TopicPharmacologyBiological Productsbusiness.industryMusculoskeletal disorderOdds ratioNon-musculoskeletal adverse eventsSerious adverse events[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good health[SDV] Life Sciences [q-bio]Clinical trial030104 developmental biologyRed yeast riceTolerability030220 oncology & carcinogenesisMeta-analysisDietary SupplementsSafetybusinessPharmacological research
researchProduct

Comparison of Unfractionated Versus Low Molecular Weight Heparin for Deep Vein Thrombosis Prophylaxis During Breast and Pelvic Cancer Surgery: Effica…

1998

In a prospective, double-blind randomized trial the efficacy and safety of low molecular weight heparin and un fractionated heparin were compared for the prevention of post operative deep vein thrombosis in patients undergoing major surgery for breast and pelvic cancer. Three hundred fifty-eight patients were randomly allocated to the two treatment groups. Thirty-four of these were excluded from the study. Of the re maining 324 patients, 164 received 5000 IU unfractionated heparin three times daily and 160 received 3000 anti-Xa units of low molecular weight heparin once daily. Treatment was started 2 to 5 hours preoperatively and continued for 7 days. The occurrence of deep vein thrombosis…

0301 basic medicinemedicine.medical_specialtymedicine.drug_classDeep veinVenographyLow molecular weight heparin030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawMedicinePlethysmographmedicine.diagnostic_testbusiness.industryHematologyGeneral MedicineHeparinmedicine.diseaseThrombosisSurgery030104 developmental biologymedicine.anatomical_structureRelative riskAnesthesiabusinessmedicine.drugClinical and Applied Thrombosis/Hemostasis
researchProduct

The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults…

2016

Supplemental Digital Content is available in the text

0301 basic medicinemyalgiaAdultCD4-Positive T-LymphocytesMalemedicine.medical_specialty4850AdolescentMedizinHIV InfectionsVacunesPlaceboAntibodies Virallaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled triallawInternal medicineVIH (Virus)medicineHumansSingle-Blind Method030212 general & internal medicineYoung adultAdverse effectAIDS VaccinesVaccinesHIV (Viruses)business.industryClinical Trial/Experimental StudyGeneral MedicineConfidence intervalCD4 Lymphocyte CountClinical trial030104 developmental biologyAnti-Retroviral AgentsImmunologyAntibody FormationComputingMethodologies_DOCUMENTANDTEXTPROCESSINGHIV-1Femalemedicine.symptombusinessViral loadResearch Article
researchProduct

Effects of Infant Formula With Human Milk Oligosaccharides on Growth and Morbidity: A Randomized Multicenter Trial

2017

Objectives:The aim of the study was to evaluate the effects of infant formula supplemented with 2 human milk oligosaccharides (HMOs) on infant growth, tolerance, and morbidity. Methods:Healthy infants, 0 to 14 days old, were randomized to an intact-protein, cow's milk-based infant formula (control, n=87) or the same formula with 1.0g/L 2fucosyllactose (2FL) and 0.5g/L lacto-N-neotetraose (LNnT) (test, n=88) from enrollment to 6 months; all infants received standard follow-up formula without HMOs from 6 to 12 months. Primary endpoint was weight gain through 4 months. Secondary endpoints included additional anthropometric measures, gastrointestinal tolerance, behavioral patterns, and morbidit…

0301 basic medicinesafetyMalePediatricsmedicine.medical_specialtyMEDLINEOligosaccharidesWeight Gainlaw.inventionbronchitis03 medical and health scienceschemistry.chemical_compound2'-FucosyllactoseRandomized controlled trialDouble-Blind Method2fucosyllactose; bronchitis; lacto-N-neotetraose; safety; tolerancelawMulticenter trialmedicineAnimalsHumansLacto-N-neotetraoseRespiratory Tract Infectionslacto-N-neotetraose2′fucosyllactose030109 nutrition & dieteticstoleranceMilk Humanbusiness.industryGastroenterologyOriginal Articles: NutritionInfant Newbornfood and beveragesInfantProtective Factorsmedicine.diseaseInfant Formula030104 developmental biologyMilkchemistryInfant formulaPediatrics Perinatology and Child Health2'fucosyllactose bronchitis lacto-N-neotetraose safety toleranceBronchitisFemalemedicine.symptombusinessWeight gainFollow-Up Studies
researchProduct